Cargando…

A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells

INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Yasutaka, Nishimura, Masuhiro, Komori, Natsuki Watanabe, Wada, Tamaki, Shirakawa, Chikage, Takenawa, Taichi, Sawamoto, Osamu, Doi, Masako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970134/
https://www.ncbi.nlm.nih.gov/pubmed/31988999
http://dx.doi.org/10.1016/j.reth.2019.10.004
_version_ 1783489453965180928
author Fujita, Yasutaka
Nishimura, Masuhiro
Komori, Natsuki Watanabe
Wada, Tamaki
Shirakawa, Chikage
Takenawa, Taichi
Sawamoto, Osamu
Doi, Masako
author_facet Fujita, Yasutaka
Nishimura, Masuhiro
Komori, Natsuki Watanabe
Wada, Tamaki
Shirakawa, Chikage
Takenawa, Taichi
Sawamoto, Osamu
Doi, Masako
author_sort Fujita, Yasutaka
collection PubMed
description INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. METHODS: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. RESULTS: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. DISCUSSION: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use.
format Online
Article
Text
id pubmed-6970134
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Japanese Society for Regenerative Medicine
record_format MEDLINE/PubMed
spelling pubmed-69701342020-01-27 A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells Fujita, Yasutaka Nishimura, Masuhiro Komori, Natsuki Watanabe Wada, Tamaki Shirakawa, Chikage Takenawa, Taichi Sawamoto, Osamu Doi, Masako Regen Ther Original Article INTRODUCTION: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. METHODS: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. RESULTS: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. DISCUSSION: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use. Japanese Society for Regenerative Medicine 2020-01-16 /pmc/articles/PMC6970134/ /pubmed/31988999 http://dx.doi.org/10.1016/j.reth.2019.10.004 Text en © 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Fujita, Yasutaka
Nishimura, Masuhiro
Komori, Natsuki Watanabe
Wada, Tamaki
Shirakawa, Chikage
Takenawa, Taichi
Sawamoto, Osamu
Doi, Masako
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_full A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_fullStr A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_full_unstemmed A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_short A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_sort pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970134/
https://www.ncbi.nlm.nih.gov/pubmed/31988999
http://dx.doi.org/10.1016/j.reth.2019.10.004
work_keys_str_mv AT fujitayasutaka apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT nishimuramasuhiro apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT komorinatsukiwatanabe apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT wadatamaki apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT shirakawachikage apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT takenawataichi apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT sawamotoosamu apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT doimasako apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT fujitayasutaka pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT nishimuramasuhiro pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT komorinatsukiwatanabe pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT wadatamaki pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT shirakawachikage pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT takenawataichi pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT sawamotoosamu pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT doimasako pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells